Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AAV
MCID: ANC002
MIFTS: 44

Anca-Associated Vasculitis (AAV)

Categories: Bone diseases, Cardiovascular diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Anca-Associated Vasculitis

About this section

MalaCards integrated aliases for Anca-Associated Vasculitis:

Name: Anca-Associated Vasculitis 20 58
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 20 58 71
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 20 58
Aav 20 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Respiratory diseases Bone diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare circulatory system diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

MESH via Orphanet 45 D056648
UMLS via Orphanet 72 C2717865
Orphanet 58 ORPHA156152
UMLS 71 C2717865
Sources

Summaries for Anca-Associated Vasculitis

About this section
GARD : 20 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, stomach, intestine, and lung. Skin lesions, such as purpura and urticaria, result when blood from small vessels leaks under the skin. AAV occurs when neutrophils attack small and medium vessels of the body. The underlying reason for this remains unclear. Treatment includes cyclophosphamide, glucocorticoids and other autoimmune drugs such as rituximab.

MalaCards based summary : Anca-Associated Vasculitis, also known as anti-neutrophil cytoplasmic antibody-associated vasculitis, is related to glomerulonephritis and churg-strauss syndrome. An important gene associated with Anca-Associated Vasculitis is PRTN3 (Proteinase 3), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Povidone and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, endothelial and eye, and related phenotypes are digestive/alimentary and hematopoietic system

Wikipedia : 74 Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis (WG), is an... more...

Sources

Related Diseases for Anca-Associated Vasculitis

About this section

Diseases related to Anca-Associated Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 745)
# Related Disease Score Top Affiliating Genes
1 glomerulonephritis 31.5 PRTN3 MPO C3
2 churg-strauss syndrome 31.4 PRTN3 MPO IL2
3 vasculitis 31.2 SERPINA1 PRTN3 MPO CTLA4 C3
4 crescentic glomerulonephritis 31.1 PRTN3 MPO
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 PTPN22 CTLA4
6 rapidly progressive glomerulonephritis 30.8 PRTN3 MPO C3
7 polyarteritis nodosa 30.8 PRTN3 MPO
8 mononeuritis multiplex 30.8 PRTN3 MPO
9 multiple cranial nerve palsy 30.7 PRTN3 MPO
10 mastoiditis 30.6 PRTN3 MPO
11 cryptogenic organizing pneumonia 30.6 PRTN3 MPO
12 goodpasture syndrome 30.6 PRTN3 MPO
13 proliferative glomerulonephritis 30.6 MPO C3
14 aortitis 30.5 PRTN3 MPO
15 exanthem 30.5 PRTN3 IL2 CTLA4
16 anti-basement membrane glomerulonephritis 30.3 PRTN3 MPO
17 orbital granuloma 30.3 PRTN3 MPO
18 pleurisy 30.3 MPO IL2
19 mononeuropathy 30.3 PRTN3 MPO
20 lymphopenia 30.3 PTPN22 IL2 CTLA4
21 adult respiratory distress syndrome 30.2 MPO HMGB1 ANGPT2
22 graves' disease 30.2 PTPN22 MPO CTLA4
23 lupus erythematosus 30.2 PTPN22 HMGB1 CTLA4 C3
24 granulomatosis with polyangiitis 30.2 SERPINA1 PTPN22 PRTN3 MPO HMGB1 CTLA4
25 autoimmune vasculitis 30.2 PRTN3 MPO IL2
26 lung disease 30.1 SERPINA1 PRTN3 MPO HMGB1
27 pneumonia 30.1 SERPINA1 MPO HMGB1
28 anemia, autoimmune hemolytic 30.0 CTLA4 C3
29 chickenpox 30.0 IL2 CTLA4
30 kidney disease 30.0 PRTN3 HMGB1 CTLA4 C3
31 scleritis 30.0 PTPN22 PRTN3 MPO CTLA4
32 respiratory failure 30.0 SERPINA1 MPO ANGPT2
33 hypersensitivity vasculitis 29.9 PRTN3 MPO C3
34 henoch-schoenlein purpura 29.9 PRTN3 MPO C3
35 ulcerative colitis 29.9 PRTN3 MPO IL2
36 allergic disease 29.9 MPO IL2 CTLA4
37 colitis 29.8 MPO IL2 CTLA4
38 diarrhea 29.8 SERPINA1 MPO IL2
39 autoimmune disease 29.8 PTPN22 PRTN3 MPO IL2 CTLA4 C3
40 vaccinia 29.8 IL2 CTLA4 C3
41 crohn's disease 29.8 PTPN22 MPO IL2 CTLA4
42 iga glomerulonephritis 29.7 SERPINA1 PRTN3 C3
43 aplastic anemia 29.7 PTPN22 MPO IL2 CTLA4
44 alpha-1-antitrypsin deficiency 29.7 SERPINA1 PRTN3 MPO
45 primary biliary cholangitis 29.6 PTPN22 PRTN3 CTLA4
46 thyroiditis 29.6 PTPN22 IL2 CTLA4
47 pulmonary disease, chronic obstructive 29.6 SERPINA1 PRTN3 MPO
48 cystic fibrosis 29.5 SERPINA1 PRTN3 MPO IL2
49 temporal arteritis 29.4 PTPN22 PRTN3 MPO IL2 CTLA4
50 rheumatoid arthritis 29.3 PTPN22 PRTN3 MPO IL2 HMGB1 CTLA4

Graphical network of the top 20 diseases related to Anca-Associated Vasculitis:



Diseases related to Anca-Associated Vasculitis
Sources

Symptoms & Phenotypes for Anca-Associated Vasculitis

About this section

MGI Mouse Phenotypes related to Anca-Associated Vasculitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.55 ANGPT2 C3 CTLA4 IL2 PTPN22
2 hematopoietic system MP:0005397 9.5 ANGPT2 C3 CTLA4 IL2 MPO PRTN3
3 immune system MP:0005387 9.17 ANGPT2 C3 CTLA4 IL2 MPO PRTN3
Sources

Drugs & Therapeutics for Anca-Associated Vasculitis

About this section

Drugs for Anca-Associated Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone Approved Phase 4 9003-39-8 131751496
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Azathioprine Approved Phase 4 446-86-6 2265
4 Anti-Infective Agents Phase 4
5 Antiparasitic Agents Phase 4
6 Antiprotozoal Agents Phase 4
7 Antimalarials Phase 4
8 Antineoplastic Agents, Immunological Phase 4
9 Anti-Inflammatory Agents Phase 4
10 Hormone Antagonists Phase 4
11 Hormones Phase 4
12 Antineoplastic Agents, Hormonal Phase 4
13 Tin Fluorides Phase 4
14 Antirheumatic Agents Phase 4
15 Immunosuppressive Agents Phase 4
16 Immunologic Factors Phase 4
17 Antimetabolites Phase 4
18 Immunoglobulins Phase 4
19 Antibodies Phase 4
20
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
21
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
22
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
23 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
24
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
25
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
26
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
27
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
28
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
29
Acetaminophen Approved Phase 3 103-90-2 1983
30
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
31
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
32
Abatacept Approved Phase 3 332348-12-6 10237
33
Mycophenolic acid Approved Phase 3 24280-93-1 446541
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
36
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
37 Folic Acid Antagonists Phase 3
38 Vitamin B Complex Phase 3
39 Vitamin B9 Phase 3
40 Folate Phase 3
41 Methylprednisolone Acetate Phase 2, Phase 3
42 Alkylating Agents Phase 2, Phase 3
43 Plasma Substitutes Phase 3
44 glucocorticoids Phase 3
45 Protective Agents Phase 3
46 Gastrointestinal Agents Phase 3
47 Neuroprotective Agents Phase 3
48 Antiemetics Phase 3
49 Antibiotics, Antitubercular Phase 3
50 Antitubercular Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
2 Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial Recruiting NCT04316494 Phase 4 Hydroxychloroquine;Placebo
3 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare Recruiting NCT02749292 Phase 4 Rituximab
4 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Active, not recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
5 Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach Terminated NCT00128895 Phase 4 azathioprine
6 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
7 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Unknown status NCT02433522 Phase 3 rituximab;Placebo
8 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
9 A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine Completed NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
10 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Completed NCT01697267 Phase 3 Azathioprine
11 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
12 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
13 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids [Standard Dose];Glucocorticoids [Reduced Dose]
14 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
15 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
16 A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis. Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
17 Evaluating Favorable, Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
18 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
19 Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE) Recruiting NCT02108860 Phase 3 Abatacept;placebo
20 Does CMV Reactivation Cause Functional Impairment of CMV Specific CD4+ T-cells? The Potential for Valaciclovir to Prevent CMV-mediated Adverse Modulation of the Immune System in Patients With ANCA-associated Vasculitis Unknown status NCT01633476 Phase 2 Valaciclovir
21 Acquired Immunodeficiency in ANCA (Antineutrophil Cytoplasmic Antibody) Associated Vasculitis Unknown status NCT03514979 Phase 2
22 A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Completed NCT02222155 Phase 2 CCX168 low dose plus standard of care;CCX168 high dose plus standard of care
23 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Resistant to Conventional Therapy Completed NCT00293072 Phase 2 Rituximab
24 Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
25 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment Completed NCT01363388 Phase 2 Placebo;CCX168
26 A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis Recruiting NCT03967925 Phase 2 Belimumab;Rituximab;Prednisolone
27 Multicenter Randomized Controlled Trial Comparing Immunogenicity and Safety of Two Innovative Anti-pneumococcal Vaccine Strategies to Standard Vaccination Regimen in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy Recruiting NCT03069703 Phase 2 Rituximab
28 A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
29 Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis Withdrawn NCT01275287 Phase 2 Standard of care treatment;eculizumab
30 Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens Withdrawn NCT01275274 Phase 2 Retinoic acid;Standard of care
31 Cohort Study of Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
32 Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis: a Pilot Study Following New Vaccine Recommendations. PneumoVas Pilot 2 Unknown status NCT02463578
33 Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation Unknown status NCT02180126
34 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
35 MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS Completed NCT02954705
36 Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Treatment of ANCA Associated Vasculitis Completed NCT00301652 mycophenolate mofetil
37 Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis. PneumoVas Pilot 1 Completed NCT02463539
38 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
39 Observational Study of Clinical Features and Outcome of Interstitial Lung Disease With Anti-neutrophil Cytoplasmic Antibody in Chinese Patients. Completed NCT04413149
40 Tailoring Maintenance Therapy to CD5+ Regulatory B Cell Recovery in ANCA Vasculitis Recruiting NCT03906227
41 A Local Interventional Study in a Cohort of Patients With GPA, MPA and EGPA (PART 2 of "Vitamin D Status in ANCA-associated Vasculitis: Analysis of RDCRN-VCRC and Local Clinic Cohorts of Patients With GPA, MPA and EGPA") Recruiting NCT04280601
42 Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis Recruiting NCT03698071
43 Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease Recruiting NCT03635385
44 Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis Recruiting NCT02257866
45 A Prospective, Multicentric, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. Recruiting NCT03290456 Prednisone 5mg/day extended of 12 additional months;Placebo 5mg/day extended of 12 additionnal months.
46 The Efficacy of Leflunomide for the Maintenance Therapy of ANCA Associated Vasculitis Not yet recruiting NCT04737343 Leflunomide;Azathioprine Tablets
47 PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS Not yet recruiting NCT04664465
48 Defining Immune Tolerance in ANCA-associated Vasculitis (AAV) Terminated NCT01934504
49 Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX) Terminated NCT02474888
50 A Prospective, Controlled Study of Double Filtration Plasmapheresis (DFPP) in Patients With Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis (AAGN) Terminated NCT02294344 CTX

Search NIH Clinical Center for Anca-Associated Vasculitis

Sources

Genetic Tests for Anca-Associated Vasculitis

About this section
Sources

Anatomical Context for Anca-Associated Vasculitis

About this section

MalaCards organs/tissues related to Anca-Associated Vasculitis:

40
Neutrophil, Endothelial, Eye, T Cells, B Cells, Monocytes, Liver
Sources

Publications for Anca-Associated Vasculitis

About this section

Articles related to Anca-Associated Vasculitis:

(show top 50) (show all 2373)
# Title Authors PMID Year
1
Immunohistochemical detection of citrullinated histone H3-positive neutrophils is useful for identifying active glomerular and interstitial lesions in antineutrophil cytoplasmic antibody-associated vasculitis. 61
32956514 2021
2
Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. 61
33595739 2021
3
Advances in ANCA-associated vasculitis and lupus nephritis. 61
33311560 2021
4
Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends. 61
33070255 2021
5
Intramedullary lesion resection as an effective treatment of spinal cord microscopic polyangiitis: a case report. 61
33608757 2021
6
Mass spectrometry-based proteomic exploration of the small urinary extracellular vesicles in ANCA-associated vasculitis in comparison with total urine. 61
33307252 2021
7
Proteomic Data Analysis for Differential Profiling of the Autoimmune Diseases SLE, RA, SS, and ANCA-Associated Vasculitis. 61
33356304 2021
8
Clinical and pathological characteristics of ANA/anti-dsDNA positive patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. 61
32964277 2021
9
[State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy]. 61
33599423 2021
10
Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society. 61
32768313 2021
11
The association between ear involvement and clinical features and prognosis in ANCA-associated vasculitis. 61
33589280 2021
12
Sequential occurrence of microscopic polyangiitis and anti-glomerular basement membrane disease in a patient with small cell lung cancer: a case report. 61
33517889 2021
13
Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. 61
33512787 2021
14
The paradoxical reaction to rituximab in six granulomatosis with polyangiitis patients: How could it be explained and managed? 61
33605863 2021
15
A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls. 61
33544216 2021
16
Muscle biopsy in anti-neutrophil cytoplasmic antibody-associated vasculitis: diagnostic yield depends on anti-neutrophil cytoplasmic antibody type, sex and neutrophil count. 61
32789447 2021
17
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. 61
33523099 2021
18
Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns. 61
33020895 2021
19
Lung adenocarcinoma and sequential antineutrophil cytoplasmic antibody-associated vasculitis: a case report. 61
33596705 2021
20
The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies. 61
33034910 2021
21
ANCA-Associated Vasculitis Management in the United States: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry. 61
33526622 2021
22
IgG4-related disease and ANCA positive vasculitis in childhood: a case-based review. 61
33590421 2021
23
Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. 61
33609106 2021
24
The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. 61
33034038 2021
25
Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis. 61
33222006 2021
26
Microscopic Polyangiitis Presenting with Splenic Infarction: A Case Report. 61
33572204 2021
27
Antimyeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in ANCA-associated-vasculitis. 61
33533909 2021
28
Allograft failure in kidney transplant recipients who developed kidney failure secondary to ANCA-associated vasculitis. 61
33527568 2021
29
Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis. 61
33585954 2021
30
Fibrinogen to albumin ratio reflects the activity of antineutrophil cytoplasmic antibody-associated vasculitis. 61
33591581 2021
31
Avacopan for the Treatment of ANCA-Associated Vasculitis. 61
33596356 2021
32
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. 61
32447389 2021
33
PEXIVAS: The End of Plasmapheresis for ANCA-Associated Vasculitis? 61
32963016 2021
34
Acute digital necrosis due to interferon-α-induced ANCA-associated vasculitis. 61
33605043 2021
35
Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'. 61
33542103 2021
36
Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh et al. 61
33542105 2021
37
Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis. A case-control study. 61
33340843 2021
38
Nasal microbiome research in ANCA-associated vasculitis: Strengths, limitations, and future directions. 61
33489010 2021
39
Lung biopsy in the diagnosis of pediatric ANCA-associated vasculitis. 61
33146463 2021
40
The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies. 61
33476813 2021
41
Management of primary vasculitides with biologic and novel small molecule medications. 61
33164993 2021
42
Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. 61
33564436 2021
43
Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis. 61
33446268 2021
44
Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression. 61
33452661 2021
45
Venous thromboembolism in ANCA-associated vasculitis. A population-based cohort study. 61
33506869 2021
46
A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis. 61
33449872 2021
47
Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis in a Case of Scleroderma After Recent Diagnosis With COVID-19. 61
33564500 2021
48
NETosis in Rheumatic Diseases. 61
33511473 2021
49
Intense immunostaining of heat shock protein 70 within renal interstitium associates with long-term renal survival in an ANCA-associated vasculitis cohort. 61
32876904 2021
50
Complement as a Therapeutic Target in Systemic Autoimmune Diseases. 61
33451011 2021
Sources

Variations for Anca-Associated Vasculitis

About this section
Sources

Expression for Anca-Associated Vasculitis

About this section
Search GEO for disease gene expression data for Anca-Associated Vasculitis.
Sources

Pathways for Anca-Associated Vasculitis

About this section

Pathways related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 12.82 SERPINA1 PTPN22 PRTN3 MPO IL2 HMGB1
2
NF-kappaB Signaling 4
11.77 PTPN22 MPO IL2 CTLA4
3
amb2 Integrin signaling 1
11 MPO HMGB1
4
T-Cell Receptor and Co-stimulatory Signaling 1
10.75 IL2 CTLA4
5
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 60
10.62 MPO HMGB1
Sources

GO Terms for Anca-Associated Vasculitis

About this section

Cellular components related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 SERPINA1 PRTN3 MPO IL2 HMGB1 C3
2 azurophil granule lumen GO:0035578 9.33 PRTN3 MPO C3
3 extracellular space GO:0005615 9.17 SERPINA1 PRTN3 MPO IL2 HMGB1 C3

Biological processes related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.61 IL2 HMGB1 C3
2 immune system process GO:0002376 9.55 PTPN22 IL2 HMGB1 CTLA4 C3
3 negative regulation of blood vessel endothelial cell migration GO:0043537 9.51 HMGB1 ANGPT2
4 T cell differentiation GO:0030217 9.49 PTPN22 IL2
5 gene expression GO:0010467 9.48 IL2 ANGPT2
6 positive regulation of interferon-beta production GO:0032728 9.46 PTPN22 HMGB1
7 positive regulation of activated T cell proliferation GO:0042104 9.4 IL2 HMGB1
8 positive regulation of interferon-alpha production GO:0032727 9.37 PTPN22 HMGB1
9 regulation of regulatory T cell differentiation GO:0045589 9.32 IL2 CTLA4
10 positive regulation of toll-like receptor 4 signaling pathway GO:0034145 9.26 PTPN22 HMGB1
11 neutrophil degranulation GO:0043312 9.02 SERPINA1 PRTN3 MPO HMGB1 C3
12 positive regulation of toll-like receptor 9 signaling pathway GO:0034165 8.96 PTPN22 HMGB1
Sources

Sources for Anca-Associated Vasculitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....